Ninlaro (Ixazomib) for amyloidosis

Overview
Ninlaro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with multiple myeloma who have received at least one prior treatment. Ninlaro is sometimes prescribed off-label to treat amyloidosis. Ninlaro is also referred to by its drug name, ixazomib.

Ninlaro is used as a targeted therapy for amyloidosis. Ninlaro is a member of a class of drugs called proteasome inhibitors. It is believed to work by targeting proteasomes inside abnormal cells, keeping them from digesting and discarding unwanted proteins. These proteins then build up in the abnormal cells, which leads to cell death.

How do I take it?
Ninlaro is the first proteasome inhibitor taken orally. Ninlaro comes in capsule form. It should be taken exactly as prescribed by the physician.

Side effects
The FDA-approved label for Ninlaro lists common side effects that include diarrhea, constipation, peripheral neuropathy (nerve problems), nausea, edema (swelling), vomiting, and back pain.

Serious side effects listed for Ninlaro include anemia (low red blood cell count); thrombocytopenia (low blood platelet count); severe diarrhea, constipation, nausea, and vomiting; severe rash; liver damage; and fetal harm.

For more details about this treatment, visit:
Ninlaro — Takeda
Ninlaro (ixazomib) — International Myeloma Foundation